M/ CLOUDY
Shionogi
The company plans to send its vaccine candidate to Phase 1 clinical trials in December, move to Phase 2 through January and seek interim approval, Shionogi CEO Isao Teshirogi said in an interview.
But a Phase 3 trial is likely due to the relative lack of COVID-19 instances in Japan, he said.
Shionogi’s plan to have enough doses to inoculate another 30 million people by the end of next year means that its effect may be much greater than that of AnGes Inc. , which first started in Osaka, which expects its first doses to be in a position until March.
“For almost national security reasons, having a capability in Japan makes a lot of sense,” Teshirogi said.
While Shionogi lags behind world leaders who have recently conducted massive clinical trials in the final phase, it is betting on a proven platform to help it become the country’s largest COVID-19 vaccine manufacturer. French pharmacist Sanofi SA and Novavax use a similar procedure in their candidate. COVID-19.
“I think our recombinant protein vaccine, from one point of view, has accumulated more knowledge about efficacy and protection than new ones,” Teshirogi said.
Newer methodologies like mNR vaccines could end up being the solution, “but to this day we know nothing,” he said.
Prime Minister Yoshihide Suga is committed to providing enough vaccines to the population until mid-2021, and Japan has entered into agreements for heaps of millions of doses with corporations such as AstraZeneca PLC and Pfizer Inc.
Shionogi earned about 42 billion yen for coVID-19 vaccine production.
But the world will want several other vaccines to combat the pandemic, given the scale of global demand, the effects on other populations, and the imaginable limits of effectiveness of the first vaccines.
Teshirogi said the Tokyo Games postponed until 2021 were “always possible,” but that they would have more diagnostic and logistical testing than vaccines.
“Getting the vaccine is not an alleged license,” he said.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights reserved.